Our 8th annual Champions of Hope Gala will be held on October 29th at the Fairmont Grand Del Mar and is expected to raise $400,000! This event will directly impact the lives of over 3.1 million (1 in 100 people) affected by Crohn’s disease or ulcerative colitis, collectively known as Inflammatory Bowel Disease (IBD).

Please consider donating to our silent auction. Your company will gain high-level visibility among 350 guests at our private event, while gaining valuable recognition throughout Southern California as a supporter of the Crohn’s & Colitis Foundation, a charitable organization that provides critical support services to over 270,000 children and adults in our area. Please see our comprehensive list of benefits for donors:

• All companies will receive recognition during the program, on the event’s auction webpage, and tagged on social media
• Gold Donor: If the value of item(s) donated exceeds $500 then the item will receive prime placement in the auction listing, company will be promoted in our e-newsletter (distributed to over 6,500 people), company name hyperlinked on our Community Partners webpage, and company’s Instagram post will be added to the Event Highlight that stays pinned to top of our Instagram page for 6 months.
• Platinum Donor: If the value of item(s) donated exceeds $750 then your donation will also be featured in the program book received by each guest at event.

This year, we are proud to be celebrating the 40th anniversary of our chapter's founding. During this special evening, we will gather to honor distinguished community members who have made an impact in the field of IBD, enjoy an exciting live and silent auction, musical entertainment, a seated dinner, cocktails, and an after-party. Our auctions are a crucial way we raise funds to drive local education and support programs that address the unique concerns of IBD patients and their caregivers. Funds are also invested in research to advance therapeutic remedies for disease management aimed at finding cures. Supporters like you are the reason we have been able to invest more than $400 million in groundbreaking research since our inception and are leading the way in IBD care.